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Abstract
Background
During the last decade, the use of 5-aminolevulinic acid (5-ALA) has been steadily increas-
ing in neurosurgery. The study's main objectives were to prospectively evaluate the effec-
tiveness and safety of 5-ALA when used in clinical practice setting on high-grade gliomas’
patients.
Methods
National, multicenter and prospective observational study. Inclusion criteria: authorized
conditions of use of 5-ALA. Exclusion criteria: contraindication to 5-ALA, inoperable or par-
tial resected tumors, pregnancy and children. Epidemiological, clinical, laboratory, radiologi-
cal, and safety data were collected. Effectiveness was assessed using complete resection
of the tumor, and progression-free and overall survival probabilities.
Results
Between May 2010 and September 2014, 85 patients treated with 5-ALA were included,
and 77 were suitable for the effectiveness analysis. Complete resection was achieved in 41
patients (54%). Surgeons considered suboptimal the fluorescence of 5-ALA in 40% of the
patients assessed. The median duration of follow-up was 12.3 months. The progression-
free survival probability at 6 months was 58%. The median duration overall survival was
14.2 months. Progression tumor risk factors were grade of glioma, age and resection
degree; and death risk factors were grade of glioma and gender. No severe adverse effects
were reported. At one month after surgery, new or increased neurological morbidity was
PLOSONE | DOI:10.1371/journal.pone.0149244 February 17, 2016 1 / 12
OPEN ACCESS
Citation: Teixidor P, Arráez MÁ, Villalba G, Garcia R,
Tardáguila M, González JJ, et al. (2016) Safety and
Efficacy of 5-Aminolevulinic Acid for High Grade
Glioma in Usual Clinical Practice: A Prospective
Cohort Study. PLoS ONE 11(2): e0149244.
doi:10.1371/journal.pone.0149244
Editor: Keith L. Black, Cedars-Sinai Medical Center,
UNITED STATES
Received: November 6, 2015
Accepted: January 28, 2016
Published: February 17, 2016
Copyright: © 2016 Teixidor et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information file.
Funding: Funding for this work was provided by the
Spanish Ministry of Health (through two research
projects which codes were: TRA-085 [convocatoria
de ayudas para el fomento de la traslación de la
aplicación de terapéutica de medicamentos de uso
humano, huérfanos y terapias avanzadas de la
Orden Ministerial SAS 2481/2009] and EC11-040
[convocatoria de ayudas para la investigación clínica
independiente de la Orden Ministerial SPI 2885/
2011]). The funders had no role in study design, data
6.5%. Hepatic enzymes were frequently increased within the first month after surgery; how-
ever, they subsequently normalized, and this was found to have no clinical significance.
Conclusion
In clinical practice, the 5-ALA showed a good safety profile, but the benefits related to 5-ALA
have not been yet clearly shown. The improved differentiation expected by fluorescence
between normal and tumor cerebral tissue was suboptimal in a relevant number of patients; in
addition, the expected higher degree of resection was lower than in clinical trials as well as
incomplete resection was not identified as a prognostic factor risk for death. Because optimal
fluorescence was correlated to higher complete resection rate, further research is needed to
identify patients (or tumors) with more surgery benefits when using the 5-ALA.
Introduction
Malignant cerebral gliomas are the most frequent type of primary cerebral tumor, as well as the
most lethal.[1,2] They tend to be diagnosed in the sixth and seventh decades of life. Although
there is a correlation between the extent of tumor resection and survival, data analysis is con-
troversial.[3,4] Complete tumor resection increases the efficacy of adjuvant treatments, such as
chemotherapy and radiotherapy.[5,6] Unfortunately, the infiltrating nature of malignant glio-
mas makes complete cytoreduction very difficult for the neurosurgeon, as the tumor margin is
easily confused with normal healthy tissue.
During the last few years, new techniques have been developed to improve the degree of
resection. These include: neuronavigation, intra-operative echography, intra-operative MRI,
and the use of 5-aminolevulinic acid (5-ALA). The 5-ALA is a biochemical precursor from the
heme group. It is administered orally leading to an accumulation of fluorescent protoporphyrin
in the malignant glioma.[7] This fluorescence can be visualized during the operation using a
modified microscope, and allows the neurosurgeon to differentiate normal cerebral tissue and
tumor tissue.
The 5-ALA was approved by the European Medicines Agency (EMA) as an orphan drug in
2007. On the contrary, in the United States, it has not been yet approved by the Food and Drug
Administration (FDA); presently, many studies are being carried out (data available in https://
clinicaltrials.gov/). The pivotal clinical trial which aimed to evaluate the efficacy of 5-ALA in
322 patients, was promptly terminated due to the beneficial results in the interim analysis
(with 270 patients included). Complete resection on MRI was achieved in 65% of the patients
treated with 5-ALA, compared to 36% of patients receiving conventional surgery with white
light.[8]
The 5-ALA effectiveness in usual clinical practice has been widely assessed in retrospective
cohort studies but not in prospective studies.[9–11] We want to point out that in the available
systematic reviews and/or metaanalysis studies related to intraoperative 5-ALA in high grade
gliomas, the efficacy data assessed were obtained from clinical trials and observational studies
together.[12,13] It is widely known that clinical trial conditions are strongly different from clin-
ical practice setting, leading to relevant differences in the obtained results.[14] To our knowl-
edge, this is the first prospective cohort study assessing the safety and the effectiveness of the
5-ALA used in multiple center clinical practice setting.
The main objectives of this study were to prospectively evaluate the effectiveness and safety
of 5-ALA when used in clinical practice setting on high-grade gliomas’ patients.
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Materials and Methods
We followed the STROBE Statement to report the study sections and their content.[15] (S1
STROBE Checklist)
In order to increase the sample size, an extension of the study was carried out; this extension
included the addition of a new participating center, the subjective assessment of the fluores-
cence intensity of 5-ALA by the neurosurgeons, and the extension of the duration of the study
to two years. The methods and results shown are from the study and its extension altogether.
Study design and patients
This is a multicenter prospective cohort study of patients with high grade glioma treated with
5-ALA before surgery. It was performed at four hospitals in Spain provided with a neurosur-
gery service: Hospital Germans Trias i Pujol (Barcelona), Hospital del Mar (Barcelona), Hospi-
tal Clínic (Barcelona), and Hospital Carlos Haya (Malaga). The ethics committee of the
coordinating centre (Comitè Ètic d’Investigació Clínica de l’Hospital Germans Trias I Pujol)
approved the study in April 2010 and its extension in May 2012. Other ethics committees of
participating centres approved the study (such as Comité Ético de Investigación Clínica IMAS,
Hospital del Mar). Eligible patients were those who met the current authorized use for 5-ALA.
Inclusion criteria were over 18 years of age, presumed radiological diagnosis of grade III or IV
glioma according to WHO classification, and forecast of complete or nearly complete surgical
resection. Exclusion criteria were any contraindication to 5-ALA, pregnancy, non-surgical
removal of the tumor, or forecast partial resection. All patients were informed about the study
and signed the informed consent before participating in the study. The recruitment study
period was fromMay 2010 to September 2014. The study ended in December 2014.
Pharmacological treatment
The drug (Gliolan1Medac, Wedel, Germany) was administered according to the product
information.[16] The administered dose was 20 mg/kg bodyweight. This was dissolved in
water (1,500 mg of 5-ALA into 50 ml of water) and delivered orally approximately 4 hours
before general anesthesia. In order to avoid severe skin reactions related to 5-ALA, the skin of
the patients was protected from the effects of UVA light and sunglasses were handed to the
patients during 24 hours after surgery.
Surgical procedure
Surgery was performed using standard microsurgical techniques. The microscope was switched
from conventional white xenon illumination to violet-blue excitation light to allow visualiza-
tion of tumor fluorescence during resection. Intra-operative neuronavigation was used in all
cases; nevertheless intra-operative ultrasound was still used in some cases. Neurosurgeons
assessed the visible fluorescence during tumor surgery resection.
Endpoints
The main endpoints of the study were drug effectiveness and drug safety.
The effectiveness endpoint was measured through the proportion of patients with histologi-
cally confirmed malignant glioma and complete resection of the tumor. Patients without histo-
logically confirmed high-grade glioma were excluded from the analysis. The volume of the
residual tumor was measured using contrast MRI performed within 5 days of surgery. The vol-
ume was calculated using manual segmentation of the tumor outline across all sections of the
MRI scan. In each center, a specialist neuroradiologist, used the same method performed this
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calculation. Complete resection was defined as no contrast enhancement or resection of more
than 95% of the initial tumor volume, otherwise was defined as non-complete resection.
The safety endpoint was assessed globally with any reported adverse events, analytical disor-
ders, and/or neurological deficits after surgery. Hematological, liver, and renal function were
assessed with a laboratory blood test, extracting a sample before surgery and at 24 hours, 48
hours, 5 days, 1 and 3 months after surgery. Neurological evaluation was used to assess clinical
status before surgery and 1, 3, and 12 months after surgery. New postoperative neurological
deficits identified at 1-month post-surgery were regarded as temporary if they had completely
recovered at 3 months post-surgery and as permanent if they persisted at 3 months post-
surgery.
Other effectiveness endpoints were overall survival (OS) and progression-free survival
(PFS) probabilities assessed at 6, 9, 12, and 24 months post-surgery. The Karnofsky Perfor-
mance Scale (KPS) was assessed before surgery.
Study size
The estimated size of the study was about 5 patients/year in each center; therefore approxi-
mately 100 patients were considered to be included in the study.
Statistical analysis
Because of skewed distributions, median, interquartile range (IQR), and range were used to
describe continuous clinical variables.
Inferential methods were used to estimate statistical significance from variable associations,
especially from the primary endpoint against the secondary endpoints. For contingency tables
and for categorical variables, exact Pearson’s χ2 test was used for comparison, and for continu-
ous variables, Wilcoxon rank sum test.
Survival analysis was performed using the Kaplan-Meier method, estimating the time from
surgery to the point of disease progression (duration of PFS) and death (duration of OS). To
compare survival between groups defined by the primary endpoint (complete resection or
incomplete resection), the log-rank test was used when the assumption of proportional risk
was met and the Wilcoxon test was used when this assumption was breached. The Cox propor-
tional risk method was used to estimate the hazard ratio (HR) between the variable categories,
after adjusting for confounding factors. This was the method followed after graphically verify-
ing the assumption of proportional risks related to the test validity. Statistical significance was
set at p<0.05. Statistical analyses were performed with SAS1 9.3 (SAS Institute Inc., Cary, NC,
USA).
Results
Between May 2010 and September 2014, 85 patients treated with 5-ALA were included in the
study. However, eight patients were subsequently excluded from the effectiveness analysis
because the histology did not confirm a high-grade glioma (oligodendroglioma grade II n = 3,
astrocitoma grade II n = 2, metastasis n = 2, and meduloblastoma n = 1).
Clinical descriptive analysis
Of the remaining 77 patients included in the analysis, 43 were men (55.8%) and the mean (SD)
age was 57.7 years (13.8); IQR 22, range 23–79 years. The baseline clinical characteristics are
shown in Table 1. Co-morbidity, such as diabetes, hypertension, cardiomyopathy, or other can-
cers, was present in 51 patients (66.2%).
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Preoperative MRI indicated that most tumors were unifocal (75 patients, 97.4%), had small
size (5 cm) (50 patients, 65%), were located in a non-eloquent brain area (41 patients,
53.2%), and were classified as type I (46 patients, 60.5%) or type II (19 patients, 24.7%) accord-
ing to Shinoda classification. The histology analysis showed 11 patients (14.3%) with grade III
glioma and 66 (85.7%) with grade IV glioma (Table 1).
The main neurological signs and symptoms before surgery were focal disorders (hemipar-
esis, aphasia or visual alterations), that were present in 39 patients (50.6%), and convulsions in
22 (28.6%). Cognitive impairment at diagnosis was present in 39 patients (50.6%). High intra-
cranial pressure was detected in 29 patients (37.7%).
The preoperative KPS score ranged from 30% to 100%, and was<80% in 15 patients
(19.5%).
Tumor resection
Complete resection was achieved in 41 patients (53.9%). No significant statistical associations
were found for resection degree (complete vs incomplete) with age, gender, hospital centre, co-
morbidities presence, preoperative KPS score, tumor size, tumor location in an eloquent brain
area, and tumor histological grade.
The MRI was performed within 3 days of surgery in 59 patients (77.6%); on the fourth day
in 11 patients (14.5%), and between the fifth and the seventh day in 6 patients (7.9%).
Table 1. Base-line characteristics of the included patients.
Included patients(n = 77)
Men 43 (55.8%)
Age (years) Median (range) 57.7 (23–79)
>55 51 (66.2%)
Co-morbidity 51 (66.2%)
Karnofsky performance scale
<70 4 (5.1%)
70–80 11 (14.1%)
>80 63 (80.8%)
Tumor location
Non-eloquent 41 (52.6%)
Eloquent 36 (47.4%)
Size tumor (cm)
5 50 (65%)
>5 27 (35%)
Shinoda score
2 points (stage I) 46 (60.5%)
3 points (stage II) 19 (25%)
 4 points (stage III) 11 (14.5%)
Histology
Grade III 11 (14.3%)
-Anaplastic astrocytoma 6
-Oligodendroglioma 3
-Oligoastrocytoma 2
Grade IV 66 (85.7%)
-Glioblastoma multiforme 65
-Gliosarcoma 1
doi:10.1371/journal.pone.0149244.t001
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Assessment of 5-ALA fluorescence: based on subjective impression of the surgeon, the
visual fluorescence of the 5-ALA was suboptimal in 40.6% of patients (13/32); on those 13
patients, the fluoresecence was of low intensity in 11, and none detected in two patients. Com-
plete resection rate was higher in patients with optimal fluorescence than in those with subopti-
mal (73.7% vs 22.2%; p = 0.0293).
Duration of surgery resection: the mean (SD) duration of the surgical procedure was 4.5
hours (57 minutes); ranging from 2.75–8 hours.
Safety
All treated patients were assessed on the safety analysis regarding adverse events. No cardiovas-
cular, gastrointestinal, or skin effects were reported. No severe or life-threatening adverse
effects were reported. For the analytical disorders and neurological deficits after surgery, all
included patients were assessed.
Regarding analytical disorders, changes in the blood count and hepatobiliary enzymes were
reported. No deterioration of renal function neither coagulation disorders were reported.
• Hematological disorders were frequent, but were mild and promptly recovered spontane-
ously. These included leukocytosis, anemia and thrombocytopenia.
• A mild and asymptomatic increase of the hepatobiliary enzymes was described. Patients with
isolated and no clinically relevant elevations of hepatic enzymes before surgery were at risk
to further increases. Alanine aminotransferase (ALT) and gamma glutamyl transferasa
(GGT) were the most frequently increased. Transaminases (AST and ALT) and bilirubin
increased at 24 hours post-surgery and GGT at day 5, and all of them decreased progressively
within the following month. Alkaline phosphatase was not altered. At 24 hours post-surgery,
the amylase enzymes values were abnormal in 34% of patients (maximum: 1,232 U/L), but
progressively normalized within the following month. (Table 2).
Referring to neurological effects, 14 patients (18.2%) presented with some degree of a new
onset of a neurological deficit or worsened the previous detected on the preoperative visit. The
most frequent deficit was the language impairments. Neurological deficit persisted in 5 patients
(35.7%) during the follow-up period, mainly on those with motor and/or a sensitive deficit. On
the contrary, all patients with seizures or status epileptic after surgery, recovered with anticon-
vulsant treatment. One month after surgery, the rate of neurological morbidity was 6.5%. All
these patients except five (64.3%) had tumor localized in an eloquent area).[17]
Survival analysis
The mean (SD) duration of follow-up was 12.3 months (7.3) (95% CI 5.7–17.7; IQR 12.01;
range 4 days–33.6 months).
Table 2. Summary of hepatobiliary disorders.
Maximum % of patients with increased value Time from drug administration Peak or Maximum value (U/L)
AST 19.2 24 hours 207
ALT 36.5 24 hours 472
GGT 37.7 Day 5 899
Bilirubin 5.4 24 hours 71 (μm/L)
Amylase 34 24 hours 1.232
AST and ALT: transaminase; GGT: gamma glutamyl transferasa
doi:10.1371/journal.pone.0149244.t002
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The median duration of PFS was 6.9 months (95% CI 5.7–9.6). PFS probability at 6, 9, 12
and 24 months was 58% (41 patients), 40% (27 patients), 35% (22 patients), and 14% (5
patients) respectively. The degree of resection (complete or incomplete) was not statistically
significant associated with the PFS (median PFS: 7.0 months [95% CI 6.1–13.6] vs. 5.7 months
[95% CI 4.2–11.2]; p = 0.17) (Fig 1). Cox proportional hazards model showed that patients
with IV grade glioma, older than 55 years, and incomplete resection degree, had an increased
risk of progression in the follow-up period (Table 3).
The median duration of OS was 14.2 months (95% CI 11.4–17.8). OS probability at 6, 9, 12,
and 24 months was 78.4% (56 patients), 68.5% (47 patients), and 59.3% (38 patients), and 22%
(7 patients), respectively. The degree of resection (complete or incomplete) was not statistically
significant associated with the OS (median OS: 16.3 months [95% CI 11.5–20.3] vs. 12.4
months [95% CI 9.0–16.6], p = 0.24) (Fig 2). Cox proportional hazards model showed that IV
grade gliomas and men had an increased risk of death in the follow-up period. (Table 4)
Surgical complications
Five patients (6.5%) undergo a surgical complication, probably not related to the 5-ALA use.
Four of them (80%) recovered and one with cerebral edema and coma was resubmitted to sur-
gery but death within the following three months.
Fig 1. Cumulative survival probability for tumor progression according to resection degree.
doi:10.1371/journal.pone.0149244.g001
Table 3. Results in a multivariate Cox proportional hazards analysis on PFS.
Variable Hazard Ratio (95% Conﬁdence Limits) P Value
Age > 55+ 55 2.05 (1.12–3.75) 0.020
Tumor degree Grade IV 2.92 (1.15–7.41) 0.024
Resection degree Incomplete 1.74 (1.01–2.98) 0.045
doi:10.1371/journal.pone.0149244.t003
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Post-hoc analysis of complementary treatment
Post-hoc exploratory analysis comparing patients treated according to the Stupp protocol,[18]
with other therapies than surgery such as radiotherapy or chemotherapy (temozolomide) were
done. There were no statistically significant differences in the PFS or in the OS when compar-
ing patients treated with all therapies (surgery + radiotherapy + chemotherapy) to patients
treated with surgery and radiotherapy or chemotherapy (p = 0.447 and p = 0.632 respectively).
Discussion
Since the EMA's approval, the use of 5-ALA has been increasing in neurosurgery, although its
use requires the neurosurgical microscope to be adapted and the neurosurgeon to be the
accredited.[16]
The most important findings in this study were 1) 5-ALA fluorescence was suboptimal in
40% of the assessed patients; 2) complete resection was achieved in 54% of patients; 3) PFS
probability at 6 months was 58% and the median duration OS was 14.2 months; 4) the high
grade of the gliomas (grade IV) is a predictor factor risk of progression and death; and 5)
5-ALA has good safety profile.
The pivotal study by Stummer et al. provided the highest level of evidence assessing the effi-
cacy of 5-ALA,[8] therefore, its main efficacy results are considered as a reference when com-
paring to the present study.
1. The neurosurgeons considered the fluorescence visually suboptimal in 40% of the patients
assessed, similar to other studies, but this was lower when using the quantitative
Fig 2. Cumulative survival probability for death according to resection degree.
doi:10.1371/journal.pone.0149244.g002
Table 4. Results in a multivariate Cox proportional hazards analysis on OS.
Variable Hazard Ratio (95% Conﬁdence Limits) P Value
Gender Male 2.03 (1.08–3.77) 0.027
Tumor degree Grade IV 3.51 (1.08–11.46) 0.038
doi:10.1371/journal.pone.0149244.t004
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fluorescence measurements.[19] The fluorescence assessment was added in the extension
study and only a third of the included patients were evaluated. However, we would like to
point out that complete resection rate was higher in patients with optimal fluorescence
than those with suboptimal fluorescence. On one hand, this assessment is subjective and
shows an impression of surgeon. On the other hand, the intensity of the fluorescence
could be variable attending to the grade or molecular characteristics of the tumor; as well
as pharmacokinetics features of the patients. At present, we are not able to identify before
surgery patients whose fluorescence will be optimal to increase drug benefits.
2. The proportion of patients with complete resection in the present study was lower than in
the pivotal study (54% vs. 63%).[8] This is probably due to several reasons. Firstly, the
expertise of the surgeons may have influenced this outcome. The intra-operative use of
fluorescence needs to be learned by the neurosurgeon. There are different shades of fluo-
rescence that are subjectively evaluated; therefore, the proficiency of the surgeon increases
with experience. In our study, the procedures were performed by different neurosurgeons,
with different levels of experience, and located in different hospitals. Secondly, in the pre-
sented study there may have been an overuse of 5-ALA by the neurosurgeons in the con-
text of 5-ALA is only approved for patients with high-grade glioma with the possibility of
nearly complete or complete resection. However, there is evidence that the neurosurgeon’s
perception of the tumor does not always represent reality. Orringer et al. suggested that
only a third of glioblastoma patients for whom the neurosurgeon predicted complete
resection achieved this radiologically.[20] Thirdly, in one out of five patients the MRI was
performed after the third day of surgery; mainly due to patients’ clinical situation, or the
inability to perform MRI in the optimal period. Afterwards, that is, from the fourth day
after surgery, non-neoplastic contrast enhancement due to surgical manipulation becomes
radiologically apparent.[21] Finally, we did not record the use of complementary intra-
operative techniques, such as echography and neuronavigation. Intra-operative tech-
niques that improve the degree of resection have been developed in the last two decades.
However, the availability of each of these techniques differs across neurosurgery depart-
ments and is changing over time. Therefore, the efficacy of each technique is difficult to
compare between hospitals. This is one of the presented study’s limitations, meaning that
we are not able to compare results according to the use of complementary intra-operative
techniques. However, our results for complete resection is similar to several other reports
of 5-ALA efficacy that have not reported the use of other intra-operative techniques in
high-risk glioma resection.[8, 19, 22]
3. In contrast to the lower proportion of patients with complete resection, the PFS probabil-
ity at 6 months was higher in this study than in the pivotal study (58% vs. 41%).[8] This
result could be explained by the highest proportion of patients with gradeIII glioma in this
study (13% vs. 2%),[8]) which have a lower recurrence rate than grade IV gliomas.[23] Nev-
ertheless, the median duration of OS was nearly 14 months in both studies.[8] This could be
explained because grade III and IV gliomas are both high-grade malignant.[23]
4. The grade of the gliomas (grade IV) as a predictor factor risk of progression and death is
an expected find related to the malignancy of the tumor. Moreover, the fact that in the
study most of the>55 years old patients (92%) and males (93%) had a glioma grade IV,
could explain this result.
Differences in efficacy results (size effect) between clinical trials and observational studies
have already been described; however it can be reduced when methodological high-quality
studies are designed.[14]
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5. Regarding the safety results, no cases of gastrointestinal, photosensitivity or hypotension
occurred in our study, contrary to described in the Gliolan1 product information (in 0.1–
1% of treated patients). In other studies, severe hypotension was present in almost 11% of
patients, mainly in whom suffer from low blood pressure already.[16,24] Photosensitivity
side effect was probably minimized by protecting the skin and eyes of patients from direct
light during 24 hours after 5-ALA was administered, similarly to described in other stud-
ies.[9]
Other side effects described were liver function and hematological disorders (10% of treated
patients).[16] More than 30% of patients had a hepatobiliary disorder, comparing to 2% of
another study;[24] this discrepancy may be due to differences in the definition of liver distur-
bance. As described in the product information, increase in the amylase range happened fre-
quently.[16] Interestingly, we observed that patients with elevated hepatic enzyme levels before
surgery needed closer monitoring post-surgery (weekly monitoring until hepatic enzyme
recovery to normal range). In addition, note that avoiding hepatotoxic drugs in all treated
patients to prevent this liver side effect is important. With this knowledge, these findings
allowed us to establish a monitoring protocol for patients with previous liver or hematological
disorders. In the same way as Stummer et al. and Wong et al., we also consider that blood cell
count disorders could be more related to surgery rather than 5-ALA administration,[8,24] and
the corticosteroids treatment could produce leukocytosis too.
Some of the observed neurological effects in the presented study could also be explained by
the mere occurrence of surgery, rather than the use of 5-ALA. The incidence of neurological
complications (6.5%) is similar to that reported in other prospective studies.[25] As expected,
the majority of those patients had already risk factor to produce neurological deficit, some of
them related to the tumor (such as size or localization), but also related to the surgery and/or
to the surgeon.
Limitations
By the nature of the design, the main limitation of this study is the absence of a control group,
meaning that we cannot compare effectiveness and safety between patients who did and did
not receive 5-ALA. Furthermore, the use of other intra-operative techniques was not recorded.
The sample size of the study is also a limitation of the conclusions drawn.
On the other hand, the strength of this study is that it is the largest multicenter prospective
study assessing the effectiveness and the safety of 5-ALA in patients with high grade glioma in
a real clinical practice setting. Prospective studies are designed with specific data collection
methods, and therefore may be more complete than retrospective studies. One disadvantage of
a prospective cohort study is the long follow-up period required to wait for events or diseases
to occur.[26] However, the latency period of gliomas is short and the risk of loss to follow-up is
very small in this population. Descriptive cohort studies often follow small group of patients.
Published studies with similar or bigger sample size to our study are retrospective and/or single
centre.[9–11]
Conclusions
In clinical practice, the 5-ALA showed a good safety profile, but the benefits related to 5-ALA
have not been yet clearly shown. The improved differentiation expected by fluorescence
between normal and tumor cerebral tissue was suboptimal in a relevant number of patients. In
addition, the expected higher degree of resection was lower than in clinical trials, as well as
incomplete resection was not identified as a prognostic factor risk for death; by contrary to
Effectiveness and Safety of 5-Aminolevulinic Acid
PLOS ONE | DOI:10.1371/journal.pone.0149244 February 17, 2016 10 / 12
glioma grade. The present conclusions require confirmation in large prospective and multicen-
ter studies. Combining different surgery tools is mandatory to better identify tumor tissue and
achieve a complete and safer resection. The results of this study suggest that the 5-ALA is not
an essential tool for high grade glioma resection, but could add some value to other tools in
guiding resection for some patients. Because optimal fluorescence was correlated to higher
complete resection rate, further research is needed to identify patients (or tumors) with more
surgery benefits when using the 5-ALA.
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